Brain CB2 receptor: a new target in medication development for treating opioid use disorder in rodents
Abstract Opioid use disorder (OUD) remains a major public health crisis, underscoring the urgent need for safer and more effective…
Zheng-Xiong Xi
Cannabinoid CB1 receptor and mu-opioid receptor interaction: new insights from conditional knockout mice
Abstract Co-administration of cannabinoids and opioids has been shown to enhance analgesic effects. However, the underlying mechanisms remain unclear. One…
Optical Intracranial Self-Stimulation (oICSS): A New Behavioral Model for Studying Drug Reward and Aversion in Rodents
Abstract Brain-stimulation reward, also known as intracranial self-stimulation (ICSS), is a commonly used procedure for studying brain reward function and…
GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice
Abstract G protein-coupled receptor 55 (GPR55) has been thought to be a putative cannabinoid receptor. However, little is known about…
GPR55 is expressed in glutamate neurons and functionally modulates nicotine taking and seeking in rats and mice
Abstract Cannabis legalization continues to progress in the USA for medical and recreational purposes. G protein-coupled receptor 55 (GPR55) is…
PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice
Abstract Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. Δ9-tetrahydrocannabinol (Δ9-THC) is a PPARγ…
PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice
Abstract Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. Δ9-tetrahydrocannabinol (Δ9-THC) is a PPARg…
Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
Abstract Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders…
Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research
Abstract Cannabinoid CB1 receptors (CB1Rs) have been major targets in medication development for the treatment of substance use disorders. However,…
β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
Abstract Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear…